TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9808381

Group type: EXPERIMENTAL
Intervention: Laparoscopic hysterectomy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Abdominal hysterectomy
Number of subjects: 40
Study: 7596208

Group type: EXPERIMENTAL
Intervention: Quality evaluation tool
Number of subjects: 101
Study: 1922869

Group type: EXPERIMENTAL
Intervention: Alternative caloric sources (branched chain amino acids, fatty acids, ketonic bodies)
Number of subjects: 0
Study: 353680

Group type: EXPERIMENTAL
Intervention: Active medications
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo medications
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Diet (cookies without artificial colors)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Diet (cookies with artificial colors)
Number of subjects: 26
Study: 31348351

Group type: EXPERIMENTAL
Intervention: Virtual reality
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-virtual reality
Number of subjects: 0
Study: 27910156

Group type: EXPERIMENTAL
Intervention: Ixekizumab Q4W (80 mg every 4 weeks after a 160 mg starting dose)
Number of subjects: 1346

Group type: EXPERIMENTAL
Intervention: Ixekizumab Q2W (80 mg every 2 weeks after a 160 mg starting dose)
Number of subjects: 1346

Group type: COMPARATOR
Intervention: Etanercept (50 mg twice weekly)
Number of subjects: 1346

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1346
Study: 25367222

Group type: EXPERIMENTAL
Intervention: BF‐FES + mirror therapy
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: FES + mirror therapy
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (conventional physical therapy program)
Number of subjects: 29
Study: 23794414

Group type: EXPERIMENTAL
Intervention: Tolvaptan (5 to 240 mg)
Number of subjects: 745
Study: 21807150

Group type: EXPERIMENTAL
Intervention: Isometric joystick
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional joystick
Number of subjects: 20
Study: 19187411

Group type: EXPERIMENTAL
Intervention: Bright light (approximately 4,000 lux)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Dim light (approximately 65 lux)
Number of subjects: 51
Study: 16899731

Group type: EXPERIMENTAL
Intervention: Neural activity in the ventromedial prefrontal cortex (vmPFC) during decision-making task.
Number of subjects: 0
Study: 17097350

Group type: EXPERIMENTAL
Intervention: Baxter Alyx (AX)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Haemonetics MCS Plus (MCS+)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Gambro Trima Accel (TA)
Number of subjects: 30
Study: 12927001

Group type: EXPERIMENTAL
Intervention: Venlafaxine (up to 150 mg/day)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Sertraline (up to 100 mg/day)
Number of subjects: 52
Study: 10071702

Group type: EXPERIMENTAL
Intervention: Concrete objective information (in addition to usual information)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Usual information
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 43
Study: 7645699

Group type: EXPERIMENTAL
Intervention: Nasal oxygen administration (up to 6 l.min‐1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Position of the sampling catheter
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mouth breathing
Number of subjects: 0
Study: 2144019

Group type: EXPERIMENTAL
Intervention: Ondansetron 5 mg/m2 IV (group A)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ondansetron 3 mg/m2 IV (group B)
Number of subjects: 20
Study: 7009593

Group type: EXPERIMENTAL
Intervention: Alprazolam (2.2 mg daily for 21 days)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Diazepam (20.2 mg daily for 21 days)
Number of subjects: 46
Study: 31387097

Group type: EXPERIMENTAL
Intervention: Molidustat in treatment-naïve patients not on dialysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Molidustat in previously ESA-treated patients not on dialysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Molidustat in previously ESA-treated patients receiving hemodialysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Molidustat in patients not receiving iron supplementation
Number of subjects: 0
Study: 28470100

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.25 µg/kg (D1)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.5 µg/kg (D2)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1.0 µg/kg (D3)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 100
Study: 25585263

Group type: EXPERIMENTAL
Intervention: Suction blister method (session 1)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Suction blister method (session 2)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Suction blister method (sessions 1 and 2)
Number of subjects: 16
Study: 23294670

Group type: EXPERIMENTAL
Intervention: Malaria-infected individuals (low, medium, high density of P. falciparum)
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Malaria-infected individuals
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Mitogen-activated T-cell populations
Number of subjects: 231

Group type: COMPARATOR
Intervention: N/A (impact of A. lumbricoides)
Number of subjects: 231
Study: 21849729

Group type: EXPERIMENTAL
Intervention: DD current therapy
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: TENS
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (functional fitness test)
Number of subjects: 80
Study: 18472391

Group type: EXPERIMENTAL
Intervention: Test of Everyday Attention for Children (TEA‐Ch)
Number of subjects: 232
Study: 16278260

Group type: EXPERIMENTAL
Intervention: Levonorgestrel (LNG) plus testosterone (T) implants
Number of subjects: 80

Group type: COMPARATOR
Intervention: Testosterone (T) implants alone
Number of subjects: 80
Study: 12921985

Group type: EXPERIMENTAL
Intervention: Homocysteine concentration >12 micromol/l
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Erythrocyte S-adenosylmethionine concentration >4000 nmol/l
Number of subjects: 231
Study: 11079650

Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 220

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 220
Study: 8677737

Group type: EXPERIMENTAL
Intervention: G‐CSF/IL‐3 combination
Number of subjects: 0

Group type: COMPARATOR
Intervention: G‐CSF alone
Number of subjects: 0
Study: 1570609

Group type: EXPERIMENTAL
Intervention: Cefamandole (1 gram intravenously 30 minutes prior to skin incision)
Number of subjects: 292

Group type: COMPARATOR
Intervention: Cefotaxime (1 gram intravenously 30 minutes prior to skin incision)
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Cefamandole
Number of subjects: 292

Group type: COMPARATOR
Intervention: Cefotaxime
Number of subjects: 292
Study: 6691892

Group type: EXPERIMENTAL
Intervention: Bopindolol
Number of subjects: 24
Study: 28833227

Group type: EXPERIMENTAL
Intervention: positive imagery
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: imagery reexperiencing
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: imagery rescripting
Number of subjects: 159

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 159
Study: 27061302

Group type: EXPERIMENTAL
Intervention: Evidence-based care (use of four validated screening tools: PEDS, PEDS-DM, M-CHAT, PHQ9)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Usual care (informal judgment including ad-hoc milestones)
Number of subjects: 54
Study: 23962728

Group type: EXPERIMENTAL
Intervention: NaFeEDTA
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Ascorbic acid
Number of subjects: 50

Group type: COMPARATOR
Intervention: Laccase
Number of subjects: 50
Study: 22689807

Group type: EXPERIMENTAL
Intervention: Lapatinib plus trastuzumab
Number of subjects: 291

Group type: COMPARATOR
Intervention: Lapatinib monotherapy
Number of subjects: 291
Study: 19930768

Group type: EXPERIMENTAL
Intervention: Energy restriction (ER)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Energy restriction with resistance training (ER+RT)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Dropouts
Number of subjects: 137
Study: 18701183

Group type: EXPERIMENTAL
Intervention: Real time continuous glucose monitoring system (RT‐CGM)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Self‐monitoring blood glucose (SMBG)
Number of subjects: 65
Study: 16012272

Group type: EXPERIMENTAL
Intervention: Rivastigmine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 12488257

Group type: EXPERIMENTAL
Intervention: New topical cysteamine formulation
Number of subjects: 36

Group type: COMPARATOR
Intervention: Standard formulation of topical cysteamine
Number of subjects: 36
Study: 11817492

Group type: EXPERIMENTAL
Intervention: Opioid taper algorithm (phase 2)
Number of subjects: 106

Group type: COMPARATOR
Intervention: No study intervention (phase 1)
Number of subjects: 106
Study: 10026666

Group type: EXPERIMENTAL
Intervention: Total Quality Management (TQM) intervention
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 2
Study: 7572652

Group type: EXPERIMENTAL
Intervention: Intensive physical exercise (> 3 hours/week) and low-fat diet
Number of subjects: 113

Group type: COMPARATOR
Intervention: Usual care by private physicians (Control)
Number of subjects: 113
Study: 1968355

Group type: EXPERIMENTAL
Intervention: Sulphasalazine (SASP)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 7258124

Group type: EXPERIMENTAL
Intervention: Commercial multivitamin‐multimineral supplement
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 31800880

Group type: EXPERIMENTAL
Intervention: Cup probe group (CPG)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Finger probe group (FPG)
Number of subjects: 25
Study: 28296771

Group type: EXPERIMENTAL
Intervention: Hands-on training (group 2, n=63)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Video demonstration (group 1, n=74)
Number of subjects: 137
Study: 26338040

Group type: EXPERIMENTAL
Intervention: Exenatide twice daily
Number of subjects: 1029

Group type: COMPARATOR
Intervention: Glimepiride
Number of subjects: 1029
Study: 24768161

Group type: EXPERIMENTAL
Intervention: Prenatal drug exposure (PDE)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Externalizing problems
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Internalizing problems (among girls)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Age and perceived peer drug use
Number of subjects: 134
Study: 22040533

Group type: EXPERIMENTAL
Intervention: Fluticasone/salmeterol (FSC) 250/50 mcg twice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tiotropium (TIO) 18 mcg once daily
Number of subjects: 0
Study: 18596686

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 17692354

Group type: EXPERIMENTAL
Intervention: Increased concentrations of PCBs and other persistent organohalogen pollutants (POPs)
Number of subjects: 310
Study: 15539049

Group type: EXPERIMENTAL
Intervention: Training group (TR)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (CN)
Number of subjects: 29
Study: 11133316

Group type: EXPERIMENTAL
Intervention: Recognition memory task with mixed 'blocked and event-related' design
Number of subjects: 0
Study: 9509948

Group type: EXPERIMENTAL
Intervention: Stripping of membranes
Number of subjects: 100

Group type: COMPARATOR
Intervention: Gentle cervical examination (Control)
Number of subjects: 100
Study: 7999928

Group type: EXPERIMENTAL
Intervention: Prestimulus of 120 ms
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Prestimulus of 200 ms
Number of subjects: 105

Group type: COMPARATOR
Intervention: Blink stimulus alone (control)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Prestimulus of 30, 60, 120, 240, 500 ms
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Prestimulus of 2000 ms
Number of subjects: 105
Study: 3052064

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Dextroamphetamine
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 30079876

Group type: EXPERIMENTAL
Intervention: Web-based Personalized Normative Feedback (PNF) with chance-based uncertainty (gamified spinners)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Web-based Personalized Normative Feedback (PNF) without chance-based uncertainty (no-spinner alcohol-only condition)
Number of subjects: 141
Study: 27930779

Group type: EXPERIMENTAL
Intervention: Home visit-based visual rehabilitation intervention (n = 35)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Waiting list control arm (n = 32)
Number of subjects: 67
Study: 23975326

Group type: EXPERIMENTAL
Intervention: 5 g oil (rapeseed) with 3 μm droplet size
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 5 g oil (rapeseed) with 0.1 μm droplet size
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 9 g oil (rapeseed) with 3 μm droplet size
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 9 g oil (rapeseed) with 0.1 μm droplet size
Number of subjects: 24
Study: 22520250

Group type: EXPERIMENTAL
Intervention: Prasugrel 10 mg daily
Number of subjects: 423

Group type: COMPARATOR
Intervention: Clopidogrel 75 mg daily
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 423

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 423
Study: 20882867

Group type: EXPERIMENTAL
Intervention: Audience Response System (ARS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Verbal response (Control)
Number of subjects: 0
Study: 17129761

Group type: EXPERIMENTAL
Intervention: Training with heavy rugby balls
Number of subjects: 14

Group type: COMPARATOR
Intervention: Training with normal rugby balls
Number of subjects: 14
Study: 16189334

Group type: EXPERIMENTAL
Intervention: Gabapentin 600 mg pre-incision
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Gabapentin 600 mg post-incision
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 16040729

Group type: EXPERIMENTAL
Intervention: 38% silver diamine fluoride (SDF) solution applied every 6 months for 36 months
Number of subjects: 425

Group type: COMPARATOR
Intervention: Control group (no SDF treatment)
Number of subjects: 425
Study: 10949635

Group type: EXPERIMENTAL
Intervention: Randomised studies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-randomised studies
Number of subjects: 0
Study: 9236963

Group type: EXPERIMENTAL
Intervention: Contests
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Direct education
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Interactive activities
Number of subjects: 55

Group type: COMPARATOR
Intervention: Kickoff event
Number of subjects: 55

Group type: COMPARATOR
Intervention: Printed materials
Number of subjects: 55
Study: 8470424

Group type: EXPERIMENTAL
Intervention: NIB-14 vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NIB-17 vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cross-reactive antibodies
Number of subjects: 0
Study: 2879960

Group type: COMPARATOR
Intervention: Propranolol (80 mg twice daily) during intravenous clorazepate administration
Number of subjects: 19

Group type: COMPARATOR
Intervention: Cigarette smoking
Number of subjects: 19
Study: 2456682

Group type: EXPERIMENTAL
Intervention: Neoton (phosphocreatine)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 27331601

Group type: EXPERIMENTAL
Intervention: Automated Natural Language Processing (NLP) algorithm
Number of subjects: 0

Group type: COMPARATOR
Intervention: Manual records review
Number of subjects: 0

Group type: COMPARATOR
Intervention: Incident reporting system
Number of subjects: 0
Study: 31173409

Group type: EXPERIMENTAL
Intervention: Modafinil
Number of subjects: 13
Study: 28032249

Group type: EXPERIMENTAL
Intervention: Acute neurological injury (ANI) patients
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Family caregivers of ANI patients
Number of subjects: 275

Group type: COMPARATOR
Intervention: Cancer patients
Number of subjects: 275

Group type: COMPARATOR
Intervention: Family caregivers of cancer patients
Number of subjects: 275
Study: 26348718

Group type: EXPERIMENTAL
Intervention: Tafluprost
Number of subjects: 41

Group type: COMPARATOR
Intervention: Latanoprost
Number of subjects: 41
Study: 23500276

Group type: EXPERIMENTAL
Intervention: Left atrial appendage closure device
Number of subjects: 547

Group type: COMPARATOR
Intervention: Warfarin therapy
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: Left atrial appendage closure device (warfarin naive subgroup)
Number of subjects: 547

Group type: COMPARATOR
Intervention: Warfarin therapy (warfarin naive subgroup)
Number of subjects: 547
Study: 22076546

Group type: EXPERIMENTAL
Intervention: Daclizumab monotherapy for 54 weeks
Number of subjects: 16
Study: 19360548

Group type: EXPERIMENTAL
Intervention: Gum chewing (one stick of sugarless gum three times per day for one hour each day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standardized postoperative care (control group)
Number of subjects: 30
Study: 16772027

Group type: EXPERIMENTAL
Intervention: PD on medication
Number of subjects: 669

Group type: COMPARATOR
Intervention: PD off medication
Number of subjects: 669

Group type: COMPARATOR
Intervention: PSP
Number of subjects: 669
Study: 11808969

Group type: EXPERIMENTAL
Intervention: Alendronate (70 mg once weekly)
Number of subjects: 277

Group type: COMPARATOR
Intervention: Placebo (once weekly)
Number of subjects: 277

Group type: COMPARATOR
Intervention: Aspirin (650 mg q.i.d. for last week)
Number of subjects: 277
Study: 10078978

Group type: EXPERIMENTAL
Intervention: Autonomous mood disorder
Number of subjects: 67

Group type: COMPARATOR
Intervention: Nonautonomous mood disorder
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Treatment completion
Number of subjects: 67
Study: 7569760

Group type: EXPERIMENTAL
Intervention: Oral cromolyn sodium (1500 mg/day) for 1 month
Number of subjects: 428

Group type: COMPARATOR
Intervention: Elimination diet
Number of subjects: 428
Study: 2160495

Group type: EXPERIMENTAL
Intervention: A&D UA-751 semi-automated cuff-oscillometric sphygmomanometer
Number of subjects: 200

Group type: COMPARATOR
Intervention: Hawksley random-zero mercury sphygmomanometer
Number of subjects: 200
Study: 6996132

Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 97

Group type: COMPARATOR
Intervention: Pyridoxine
Number of subjects: 97
Study: 29976188

Group type: EXPERIMENTAL
Intervention: Structured yoga intervention consisting of five days of structured yoga training and practice at home for 90 days, along with two hours of health education on lifestyle modifications.
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control group receiving two hours of health education on lifestyle modifications only.
Number of subjects: 140
Study: 27206923

Group type: EXPERIMENTAL
Intervention: Xenograft bone‐substitute material (Bio‐Oss Collagen®) placed in the fresh sockets along with immediate denture placement
Number of subjects: 34

Group type: COMPARATOR
Intervention: Conventional treatment including denture placement immediately after extractions
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Xenograft bone‐substitute material (Bio‐Oss Collagen®)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 34
Study: 25626409

Group type: EXPERIMENTAL
Intervention: 0.50 mmol vinegar (6% acetic acid)
Number of subjects: 8
Study: 23107353

Group type: EXPERIMENTAL
Intervention: Insulin infusion site warming device (InsuPatch)
Number of subjects: 13

Group type: COMPARATOR
Intervention: No InsuPatch activation (Control)
Number of subjects: 13
Study: 21435365

Group type: EXPERIMENTAL
Intervention: Solid breakfast (oatmeal, blueberries, and apples)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Liquid breakfast (fruit juices and skim milk)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Both meals (solid and liquid)
Number of subjects: 14
Study: 18855229

Group type: EXPERIMENTAL
Intervention: Community skills training (local shops)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Classroom-based training
Number of subjects: 40

Group type: COMPARATOR
Intervention: Community-based training
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 40
Study: 16785373

Group type: EXPERIMENTAL
Intervention: Intensive educational intervention
Number of subjects: 202

Group type: COMPARATOR
Intervention: Standard education
Number of subjects: 202
Study: 12837861

Group type: EXPERIMENTAL
Intervention: Exercise group (n = 12); daily extension and flexion range of motion against passive resistance (5 minutes per day, 5 days per week, for 4 weeks)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (n = 12)
Number of subjects: 24
Study: 10894281

Group type: EXPERIMENTAL
Intervention: d4T‐3TC‐IDV
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: ZDV‐3TC‐IDV
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: d4T‐ddI‐IDV
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 109
Study: 8794955

Group type: EXPERIMENTAL
Intervention: Inhaled methanol at 200 ppm for 4 hours
Number of subjects: 22
Study: 2004725

Group type: EXPERIMENTAL
Intervention: 0.8 mg intravitreal dexamethasone phosphate
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control (no injection)
Number of subjects: 57
Study: 6346848

Group type: COMPARATOR
Intervention: Hydrochlorothiazide, 50 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Indapamide, 2.5 mg
Number of subjects: 0
Study: 29691794

Group type: EXPERIMENTAL
Intervention: ASAP intervention
Number of subjects: 161

Group type: COMPARATOR
Intervention: Business-as-usual control
Number of subjects: 161
Study: 26282583

Group type: EXPERIMENTAL
Intervention: Increased sedentary time (SED-time)
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Increased physical activity energy expenditure (PAEE)
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Kidney function measures (eGFR, serum creatinine, urine ACR)
Number of subjects: 326
Study: 24636035

Group type: EXPERIMENTAL
Intervention: In-person training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Web-based training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mailed materials
Number of subjects: 0

Group type: COMPARATOR
Intervention: All groups (including control)
Number of subjects: 0
Study: 23104075

Group type: EXPERIMENTAL
Intervention: Home visiting (HV)
Number of subjects: 643

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 643
Study: 20737518

Group type: EXPERIMENTAL
Intervention: Multi-vitamin/mineral supplement (Supradyn)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 216